Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/12/2025
Locations: Emory University School of Medicine- Human Genetics- Site Number : 840060, Decatur, Georgia
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Register for Updates
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919
Recruiting
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Gender:
ALL
Ages:
Between 1 year and 3 years
Trial Updated:
08/11/2025
Locations: Emory University - Children's Healthcare of Atlanta, Inc., Atlanta, Georgia
Conditions: Allergy, Peanut Allergy
Register for Updates
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/11/2025
Locations: Atlanta Center for Medical Research, Atlanta, Georgia
Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Register for Updates
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961
Recruiting
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Hamilton Research, LLC, Alpharetta, Georgia
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922
Recruiting
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Southeast Retina Center, Augusta, Georgia
Conditions: Diabetic Macular Edema
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984
Recruiting
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/11/2025
Locations: Advanced Discovery Research, Atlanta, Georgia
Conditions: Agitation, Alzheimer Disease
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/11/2025
Locations: Advanced Discovery Research, Atlanta, Georgia
Conditions: Major Depressive Disorder
Register for Updates
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014
Recruiting
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Pos... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
08/11/2025
Locations: Accel Neurosciences, Decatur, Georgia
Conditions: Early Alzheimers Disease
Register for Updates
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060
Recruiting
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent i... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/11/2025
Locations: Research Site, Albany, Georgia
Conditions: Heart Failure
Register for Updates
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Recruiting
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
08/11/2025
Locations: Javarra and Privia Med, Savannah, Georgia
Conditions: Female Contraception
Register for Updates
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085
Recruiting
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Lymphoma
Register for Updates
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
NCT06619561
Recruiting
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Chronic Graft-Versus-Host Disease (cGVHD)
Register for Updates